-+ 0.00%
-+ 0.00%
-+ 0.00%
Minerva Neurosciences Expects Roluperidone C19 Trial Results in Second Half of Next Year
Share
Listen to the news
Minerva Neurosciences Expects Roluperidone C19 Trial Results in Second Half of Next Year
  • Minerva Neurosciences presented new analyses supporting roluperidone’s potential to improve primary negative symptoms and daily functioning in schizophrenia.
  • Earlier trials produced mixed efficacy results, although both showed improvements in daily functioning compared with placebo.
  • The ongoing C19 trial remains on track for initial results in the second half of next year.
  • FDA declined marketing approval in February 2024, citing insufficient evidence of effectiveness from the previous studies.
  • The targeted U.S. population represents about 900,000 patients, with an estimated market opportunity exceeding $2 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Minerva Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-462005), on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending